Author Affiliations: School of Medicine and Pharmacology, Sir Charles Gairdner Hospital Unit (Drs Lewis, Prince, and Zhu) and Royal Perth Hospital Unit (Dr Hodgson), University of Western Australia, Perth, Australia; Departments of Endocrinology and Diabetes (Drs Lewis, Prince, and Zhu) and Cardiovascular Medicine (Dr Thompson), Sir Charles Gairdner Hospital, Perth; and School of Exercise, Biomedical and Health Science, Edith Cowan University, Joondalup, Australia (Dr Devine).
Cocoa, the principal ingredient of chocolate, is a rich source of flavonoids. Higher flavonoid intakes are associated with a lower risk of cardiovascular disease, and flavonoid-rich cocoa and chocolate can reduce blood pressure and improve endothelial function.1 Interest in the potential of cocoa and chocolate to prevent cardiovascular disease has been stimulated by recent prospective cohort studies in which consuming more than 2.25 g/d of cocoa (average, 4.2 g/d) was associated with a 50% lower risk of cardiovascular mortality.2,3 Our objective was to investigate the relationship between chocolate consumption and atherosclerotic vascular disease (ASVD) events in a prospective study of older women followed up for 9.5 years. In formulating our prespecified analytical protocol, we hypothesized that the greatest benefit on ASVD risk would likely be for women with daily exposure to the cocoa flavonoids because, to date, much of the reported benefits of cocoa flavonoids on nitric oxide metabolism and endothelial function are short term.4
The participants were recruited in 1998 to a 5-year randomized controlled trial of calcium supplements as described previously.5 At baseline, information on food and beverage consumption frequency, medical history and current medications as verified by their general practitioner, physical activity, and socioeconomic status were collected from 1216 women using previously validated questionnaires. The frequency of chocolate consumption was collapsed into the following 3 categories: less than 1 serving/wk (rarely), 1 to 6 servings/wk (weekly), and 7 or more servings/wk (daily). A serving of chocolate weighing 25 to 50 g containing 5% to 15% cocoa by weight is equivalent to a cocoa intake among frequent chocolate consumers of approximately 1 to 5 g/d. The presence of carotid focal plaques and common carotid artery intima-media thickness (CCA-IMT) were assessed once during the study by B-mode carotid ultrasonography. Plaque was defined as a clearly identified area of focal increased thickness (≥1 mm) of the intima-media layer. The Western Australian Data Linkage System (WADLS) was used to assess clinical outcomes. This provides a validated record of every hospitalization (from the coded discharge record) and cause of death (from the death certificate) for residents of Western Australia. The use of this data system allows complete ascertainment of verified ASVD events independently of patient report, with the associated problems of loss to follow-up and inaccurate reporting.6 Atherosclerotic vascular disease events were defined using diagnosis codes from the International Statistical Classification of Diseases and Related Health Problems, 10th Revision, Australian Modification (ICD-10-AM).7 The primary outcome was ASVD events causing either death or hospitalization retrieved from WADLS for each of the study participants from 1998 until 2008.
Of the 1216 participants, 579 (47.6%) had less than 1 serving of chocolate weekly (rarely), 435 (35.8%) had between 1 and 6 servings/wk (weekly), and 202 (16.6%) had at least 7 servings/wk (daily). There were 158 ASVD events (27.3%) in the group that rarely consumed chocolate, compared with 90 events (20.7%) in the group that consumed chocolate weekly, and 42 events (20.8%) in the group that consumed chocolate daily. Because the demographic and outcomes data in the weekly and daily group were similar and because grouping them together to produce a “frequently” group split the cohort at the median frequency of chocolate ingestion, a comparison of the rarely (<1 serving/wk) and frequently (≥1 serving/wk) groups was undertaken.
Results from ASVD event analyses showed that hospitalization or death was less common in participants who consumed chocolate frequently (Table). Compared with women who rarely consumed chocolate, those who consumed chocolate frequently had a significantly lower risk of hospitalization for or death from ishemic heart disease and heart failure in both age and multivariable-adjusted analyses (Table). Women who frequently consumed chocolate also had a significantly lower prevalence of carotid atherosclerotic plaques compared with women who consumed chocolate rarely, but there was no effect on the mean CCA-IMT by age or multivariable-adjusted analysis of variance.
The data from this prospective cohort study of elderly women are the first, to our knowledge, to show an association between chocolate consumption and carotid atherosclerotic plaque prevalence and provide further evidence that chocolate intake may be protective against atherosclerotic vascular disease events. These data also suggest that weekly chocolate consumption may be as effective as daily consumption to obtain the cardiovascular benefit, since we found similar risk reductions of 24% among daily and weekly chocolate consumers. Furthermore, the association between atherosclerotic plaque prevalence but not CCA-IMT suggests that the effect of habitual chocolate consumption may be primarily on ischemic heart disease risk rather than cerebrovascular disease risk, which is more strongly associated with CCA-IMT.8 The observed association between chocolate consumption and atherosclerotic vascular disease is from a prospective study and as such cannot prove causality. However, given the size of the observed risk reduction associated with frequent chocolate consumption for atherosclerotic plaques and atherosclerotic cardiovascular disease, it would be possible to mount a well-designed randomized controlled trial to determine if indeed cocoa or chocolate would be a safe, acceptable method of reducing atherosclerotic cardiovascular disease in addition to current approaches to the treatment and prevention of atherosclerotic vascular disease.
Correspondence: Dr Lewis, School of Medicine and Pharmacology, Sir Charles Gairdner Hospital, Hospital Avenue, Nedlands, Perth, WA 6009, Australia (firstname.lastname@example.org).
Author Contributions:Study concept and design: Lewis and Prince. Acquisition of data: Lewis, Prince, Devine, and Thompson. Analysis and interpretation of data: Lewis, Prince, Zhu, Devine, Thompson, and Hodgson. Drafting of the manuscript: Lewis, Prince, and Hodgson. Critical revision of the manuscript for important intellectual content: Lewis, Prince, Zhu, Devine, Thompson, and Hodgson. Statistical analysis: Lewis, Prince, Zhu, and Hodgson. Obtained funding: Prince and Devine. Administrative, technical, and material support: Lewis, Prince, and Thompson. Study supervision: Prince.
Financial Disclosure: None reported.
Funding/Support: The study was supported by a research grant from Healthway Health Promotion Foundation of Western Australia and by the project grants 254627, 303169, and 572604 from the National Health and Medical Research Council of Australia.
Additional Contributions: The staff at the Data Linkage Branch, Hospital Morbidity Data Collection and Registry of Births, Deaths, and Marriages provided the data for this study.
This article was corrected online for typographical errors on 11/8/2010.
Thank you for submitting a comment on this article. It will be reviewed by JAMA Internal Medicine editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 8
Customize your page view by dragging & repositioning the boxes below.
Users' Guides to the Medical Literature
Interpreting Apparently "Positive" Trials
All results at
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.